The selective noradrenaline re-uptake inhibitor reboxetine has an early onset of antidepressant action

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 4, 2000, Pages 293-297

  Versiani, M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Clinical trial; Onset; Placebo comparison; Reboxetine; Selective NRI

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; REBOXETINE;

ANXIETY; ARTICLE; ATTITUDE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIAPHORESIS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0034527679     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500050517858     Document Type: Article

References (14)

1. Epidemiology of depression
2. Suicide and antidepressants
3. Antidepressants: Can we determine how quickly they work? Issues from the literature
4. Reboxetine: Additional benefits to the depressed patient
5. Reboxetine: A review of antidepressant tolerability
6. A double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder
7. A rating scale for depression
8. A self-rating depression scale
9. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
10. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia
11. Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning
12. Predicting the short-term outcome of first episodes and recurrences of clinical depression: A prospective study of life events, difficulties, and social support networks